279 related articles for article (PubMed ID: 20732813)
1. Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
Lin S; Wrobleski ST; Hynes J; Pitt S; Zhang R; Fan Y; Doweyko AM; Kish KF; Sack JS; Malley MF; Kiefer SE; Newitt JA; McKinnon M; Trzaskos J; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Oct; 20(19):5864-8. PubMed ID: 20732813
[TBL] [Abstract][Full Text] [Related]
2. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
3. Indolin-2-one p38α inhibitors I: design, profiling and crystallographic binding mode.
Eastwood P; González J; Gómez E; Vidal B; Caturla F; Roca R; Balagué C; Orellana A; Domínguez M
Bioorg Med Chem Lett; 2011 Jul; 21(14):4130-3. PubMed ID: 21696951
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of 6-anilinoindazoles as selective inhibitors of c-Jun N-terminal kinase-3.
Swahn BM; Huerta F; Kallin E; Malmström J; Weigelt T; Viklund J; Womack P; Xue Y; Ohberg L
Bioorg Med Chem Lett; 2005 Nov; 15(22):5095-9. PubMed ID: 16140012
[TBL] [Abstract][Full Text] [Related]
5. 5-amino-pyrazoles as potent and selective p38α inhibitors.
Das J; Moquin RV; Dyckman AJ; Li T; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Newitt JA; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2010 Dec; 20(23):6886-9. PubMed ID: 21035336
[TBL] [Abstract][Full Text] [Related]
6. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1.
Tynebor RM; Chen MH; Natarajan SR; O'Neill EA; Thompson JE; Fitzgerald CE; O'Keefe SJ; Doherty JB
Bioorg Med Chem Lett; 2011 Jan; 21(1):411-6. PubMed ID: 21084192
[TBL] [Abstract][Full Text] [Related]
8. Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo.
Luke RW; Ballard P; Buttar D; Campbell L; Curwen J; Emery SC; Griffen AM; Hassall L; Hayter BR; Jones CD; McCoull W; Mellor M; Swain ML; Tucker JA
Bioorg Med Chem Lett; 2009 Dec; 19(23):6670-4. PubMed ID: 19854647
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
11. The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
Wrobleski ST; Lin S; Dhar TG; Dyckman AJ; Li T; Pitt S; Zhang R; Fan Y; Doweyko AM; Tokarski JS; Kish KF; Kiefer SE; Sack JS; Newitt JA; Witmer MR; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2013 Jul; 23(14):4120-6. PubMed ID: 23746475
[TBL] [Abstract][Full Text] [Related]
12. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and biophysical characterization of unique switch pocket inhibitors of p38α.
Swann SL; Merta PJ; Kifle L; Groebe D; Sarris K; Hajduk PJ; Sun C
Bioorg Med Chem Lett; 2010 Oct; 20(19):5787-92. PubMed ID: 20471255
[TBL] [Abstract][Full Text] [Related]
14. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity.
Angell R; Aston NM; Bamborough P; Buckton JB; Cockerill S; deBoeck SJ; Edwards CD; Holmes DS; Jones KL; Laine DI; Patel S; Smee PA; Smith KJ; Somers DO; Walker AL
Bioorg Med Chem Lett; 2008 Aug; 18(15):4428-32. PubMed ID: 18614366
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 5-substituted-N-arylpyridazinones as inhibitors of p38 MAP kinase.
Jerome KD; Hepperle ME; Walker JK; Xing L; Devraj RV; Benson AG; Baldus JE; Selness SR
Bioorg Med Chem Lett; 2010 May; 20(10):3146-9. PubMed ID: 20395140
[TBL] [Abstract][Full Text] [Related]
16. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
17. Discovery of highly selective and potent p38 inhibitors based on a phthalazine scaffold.
Herberich B; Cao GQ; Chakrabarti PP; Falsey JR; Pettus L; Rzasa RM; Reed AB; Reichelt A; Sham K; Thaman M; Wurz RP; Xu S; Zhang D; Hsieh F; Lee MR; Syed R; Li V; Grosfeld D; Plant MH; Henkle B; Sherman L; Middleton S; Wong LM; Tasker AS
J Med Chem; 2008 Oct; 51(20):6271-9. PubMed ID: 18817365
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase.
Sack JS; Kish KF; Pokross M; Xie D; Duke GJ; Tredup JA; Kiefer SE; Newitt JA
Acta Crystallogr D Biol Crystallogr; 2008 Jul; D64(Pt 7):705-10. PubMed ID: 18566506
[TBL] [Abstract][Full Text] [Related]
19. Two classes of p38alpha MAP kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes.
Michelotti EL; Moffett KK; Nguyen D; Kelly MJ; Shetty R; Chai X; Northrop K; Namboodiri V; Campbell B; Flynn GA; Fujimoto T; Hollinger FP; Bukhtiyarova M; Springman EB; Karpusas M
Bioorg Med Chem Lett; 2005 Dec; 15(23):5274-9. PubMed ID: 16169718
[TBL] [Abstract][Full Text] [Related]
20. Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.
Coumar MS; Tsai MT; Chu CY; Uang BJ; Lin WH; Chang CY; Chang TY; Leou JS; Teng CH; Wu JS; Fang MY; Chen CH; Hsu JT; Wu SY; Chao YS; Hsieh HP
ChemMedChem; 2010 Feb; 5(2):255-67. PubMed ID: 20039358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
